Amedica Corporation (NASDAQ:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is pleased to announce the release of its Valeo II™ C interbody fusion device system. The second generation cervical system will be commercially available mid-February 2016.
The Valeo II C interbody fusion device, made entirely of Amedica’s micro composite silicon nitride biomaterial, offers a slim-profile design which improves intraoperative visibility for more exact placement and postoperative visibility, providing better assessment of successful fusion. The new design also includes directional teeth to resist expulsion, an anterior thread connection for improved inserter stability, and a 14x12mm footprint size for smaller patients. Accompanying the revised implants are new consolidated, single-level instrumentation sets with improved ergonomics and ease of use.
“As I began using the second generation Amedica silicon nitride cervical interbody in my first few cases, it become very evident to me the ease of use this system offers, as well as the clinical benefits my patients were experiencing over allograft,” said Dr. David M. Jones, MD, Piedmont Neurosurgery and Spine, Hickory, NC. “The new innovative design coupled with this unique biomaterial can revolutionize spinal fusion procedures, and ensure a level of inter-operative and post-operative accuracy that is unparalleled today.”
“We are very excited to supplement this innovative product line with an additional second generation interbody offering,” said Dr. Sonny Bal, Chairman and CEO of Amedica Corporation. “Because of silicon nitride’s unique imaging and osteointegration properties and the improved design, surgeons are able to assess fusion more effectively and earlier in the healing process. The feedback received from our limited release has been extremely positive and very encouraging for our vision of the widespread adoption of silicon nitride as the ideal material for spine fusion.”
The Valeo II C interbody fusion device is made of micro composite silicon nitride biomaterial, which offers a favorable environment for bone growth and osteointegration, when compared to competitive PEEK and titanium offerings. Valeo II silicon nitride interbody fusion devices are also semi-radiolucent with clearly visible boundaries in x-rays and produce no artifacts under MRI or CT scans. The combination of these properties is found only in Amedica’s silicon nitride biomaterial technology.
The Valeo C family of products is the first to receive FDA clearance for two-level cervical interbody cage indications. Valeo cervical fusion devices are indicated for use in skeletally mature patients with degenerative disc disease at one disc level or two contiguous levels and are designed for use with autograft or allograft to facilitate fusion. (Original Source)
Shares of Amedica closed last Friday at $0.105. AMDA has a 1-year high of $0.88 and a 1-year low of $0.09. The stock’s 50-day moving average is $0.12 and its 200-day moving average is $0.31.
On the ratings front, Needham analyst Michael Matson reiterated a Buy rating on AMDA, with a price target of $1, in a report issued on November 13. The current price target represents a potential upside of 809.1% from where the stock is currently trading. According to TipRanks.com, Matson has a total average return of -4.2%, a 42.9% success rate, and is ranked #3195 out of 3608 analysts.
Amedica Corporation is a commercial-stage biomaterial company. It is engaged in using its silicon nitride technology platform to develop, manufacture & commercialize medical devices. Its products include valeo interbody fusion devices & facet fixation.